Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second of two planned phase III trials of eprotirome for the treatment of heterozygous familial hypercholesterolaemia

Trial Profile

Second of two planned phase III trials of eprotirome for the treatment of heterozygous familial hypercholesterolaemia

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eprotirome (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Registrational; Therapeutic Use
  • Sponsors Karo Bio

Most Recent Events

  • 14 Feb 2012 Status changed from planning to discontinued, according to a Karo Bio media release.
  • 07 Oct 2011 Not official study title
  • 27 Aug 2010 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top